European Archives - Page 6 of 1042 - European Medical Journal

The Second Brain: Transforming Gut Healing: Part 2

In this second part of the podcast, Jonathan welcomes back Douglas Drossman, pioneer in disorders of gut-brain interaction.

STI Surge in Europe Sparks Public Health Concern

The ECDC’s Annual Epidemiological Reports analysed surveillance data from 29 EU/EEA countries, tracking trends in gonorrhoea, syphilis, and chlamydia.

Coeliac Disease Risk Drops with High-Fibre Diet in Infants

A new study suggests that infants who consume a high-fibre diet before their first birthday may have a significantly lower risk of developing celiac disease.

Which Treatment for Basal Cell Carcinoma is More Effective?

After five years, the probability of remaining free from treatment failure was 77.8% for patients who underwent superficial curettage.

FDA fast-tracks Boehringer's NSCLC drug review

The FDA has granted priority review to zongertinib for non-small cell lung cancer (NSCLC).

OCEAN(a)-DOSE Trial: New Data on Lipoprotein(a) and Oxidised Phospholipids

Olpasiran significantly lowers oxidized phospholipids on apolipoprotein B but has no impact on systemic inflammatory markers in cardiovascular disease.

New Study Explores ctDNA in Urothelial Cancer Treatment

Researchers aimed to establish a plasma ctDNA sequencing assay and evaluate its effectiveness in assessing tumour genetics and treatment response.

Optimising Patient Outcomes in Advanced Gastrointestinal Stromal Tumours (GIST) in Europe

The European Society for Medical Oncology (ESMO) guidelines recommend life-long systemic tyrosine kinase inhibitor (TKI) therapies for…

Rezivertinib Outperforms Gefitinib in NSCLC Treatment Study

A Phase III trial has shown that rezivertinib offers superior progression-free survival compared to gefitinib as a first-line treatment in EGFR-mutated locally advanced or metastatic non-small-cell lung cancer.

Combined Ultrasound Technique Reliable for Ruling Out N2 Disease in Lung Cancer Patients

Study shows combined endobronchial ultrasound and endoscopic ultrasound (CUS) is a highly reliable tool for ruling out N2 disease in patients with PET-negative lung cancer.